Importantly, upregulation of components of the PI3K/AKT/mTOR pathway has been reported in SMO resistant medulloblastomas and concurrent combination of SMO antagonists with PI3K/mTOR inhibitors blocks tumour growth and prevents the development of resistance to SMO inhibitors19,20. The gene discussed is AKT1; the disease is medulloblastoma.